A comparison of the PDC drug sensitivity and clinical tumor response showed that the PDC AUC values for EGFR- or ALK-TKIs were significantly associated with the clinical tumor response (median standardized AUC values: −0.78 in PR, −0.29 in SD, and 0.30 in PD; p < 0.001; Figure 3A). Here, ALK is linked to neoplasm.